ImmunityBio Faces Class Action Lawsuit for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy IBRX?
Source: Globenewswire
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, seeking damages for investors who purchased the company's securities between January 19 and March 24, 2026, indicating strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, resulting in the company's statements about its business, operations, and prospects being deemed materially false and misleading, which could lead to significant losses for investors.
- Investor Action Guidance: Affected investors must apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery from the lawsuit, highlighting the importance of legal processes in protecting investor rights.
- No-Risk Representation: Bronstein, Gewirtz & Grossman, LLC offers contingency fee representation, charging fees only upon successful recovery, which enhances investor confidence in participating in the class action lawsuit.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.280
Low
5.00
Averages
7.33
High
9.00
Current: 7.280
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Faces Class Action Lawsuit for Securities Violations
- Class Action Filed: Lowey Dannenberg P.C. has announced a class action lawsuit against ImmunityBio for violations of federal securities laws, representing investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, during the specified Class Period.
- Allegations of Misrepresentation: The lawsuit alleges that ImmunityBio's officer Soon-Shion materially overstated Anktiva's capabilities, resulting in materially false and misleading statements regarding the company's business, operations, and prospects, which misled investors.
- Stock Price Decline: Following the revelation of the truth, ImmunityBio's common stock experienced a precipitous decline, injuring investors, particularly those who suffered losses exceeding $100,000, thereby exacerbating their financial distress.
- Call to Action for Investors: The lawsuit urges any investor wishing to serve as Lead Plaintiff to act before May 26, 2026, highlighting the urgency of the case and the firm's commitment to protecting affected investors' interests.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a class action lawsuit for securities fraud, alleging material misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, potentially leading to significant investor losses.
- Stock Price Plunge: Following an FDA warning on March 24, 2026, regarding false claims about Anktiva, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, indicating severe market concerns about the company's future prospects.
- Investor Action: Affected investors are encouraged to file for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free consultations, emphasizing that investors' rights to recovery remain intact regardless of their participation as lead plaintiffs.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud class actions, having recovered over $25 billion for clients, showcasing its significant expertise and influence in the securities litigation landscape.
See More
ImmunityBio Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, seeking damages for investors who purchased the company's securities between January 19 and March 24, 2026, indicating strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, resulting in the company's statements about its business, operations, and prospects being deemed materially false and misleading, which could lead to significant losses for investors.
- Investor Action Guidance: Affected investors must apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery from the lawsuit, highlighting the importance of legal processes in protecting investor rights.
- No-Risk Representation: Bronstein, Gewirtz & Grossman, LLC offers contingency fee representation, charging fees only upon successful recovery, which enhances investor confidence in participating in the class action lawsuit.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, allowing potential compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that executives made false statements regarding Anktiva's capabilities during the Class Period, resulting in investor losses when the truth emerged, highlighting significant governance and disclosure issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, as well as being ranked first for the number of settlements in 2017, indicating its expertise and success in this field.
- Investor Guidance: Investors are advised to select counsel with a proven track record rather than firms that merely act as intermediaries, ensuring they receive the best representation and support in litigation.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading statements made by its Chief Scientific Officer regarding Anktiva's efficacy during a podcast, involving investors from January 19 to March 24, 2026, highlighting significant risks in the company's information disclosure practices.
- FDA Warning Impact: The FDA issued a warning letter to ImmunityBio, indicating that its promotional materials misrepresented Anktiva's efficacy, resulting in a more than 21% drop in stock price on March 24, 2026, erasing nearly $2 billion in market capitalization, demonstrating the direct impact of regulatory risks on shareholder confidence.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to submit claims, reflecting the market's heightened concern over the company's transparency and compliance.
- Public Health Risks: The FDA emphasized that ImmunityBio's promotional materials could pose a public health threat due to misleading claims about Anktiva's efficacy, further underscoring the company's accountability issues in market promotion.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, or risk losing representation in the class action.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, allowing them to seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that executives at ImmunityBio made false or misleading statements during the class period, resulting in investor losses when the true information was revealed, indicating significant issues with the company's business and prospects.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling similar cases.
See More
ImmunityBio Faces Class Action Lawsuit for Securities Violations
- Class Action Filed: Lowey Dannenberg P.C. has announced a class action lawsuit against ImmunityBio for violations of federal securities laws, representing investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, during the specified Class Period.
- Allegations of Misrepresentation: The lawsuit alleges that ImmunityBio's officer Soon-Shion materially overstated Anktiva's capabilities, resulting in materially false and misleading statements regarding the company's business, operations, and prospects, which misled investors.
- Stock Price Decline: Following the revelation of the truth, ImmunityBio's common stock experienced a precipitous decline, injuring investors, particularly those who suffered losses exceeding $100,000, thereby exacerbating their financial distress.
- Call to Action for Investors: The lawsuit urges any investor wishing to serve as Lead Plaintiff to act before May 26, 2026, highlighting the urgency of the case and the firm's commitment to protecting affected investors' interests.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a class action lawsuit for securities fraud, alleging material misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, potentially leading to significant investor losses.
- Stock Price Plunge: Following an FDA warning on March 24, 2026, regarding false claims about Anktiva, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, indicating severe market concerns about the company's future prospects.
- Investor Action: Affected investors are encouraged to file for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free consultations, emphasizing that investors' rights to recovery remain intact regardless of their participation as lead plaintiffs.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud class actions, having recovered over $25 billion for clients, showcasing its significant expertise and influence in the securities litigation landscape.
See More
ImmunityBio Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, seeking damages for investors who purchased the company's securities between January 19 and March 24, 2026, indicating strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, resulting in the company's statements about its business, operations, and prospects being deemed materially false and misleading, which could lead to significant losses for investors.
- Investor Action Guidance: Affected investors must apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery from the lawsuit, highlighting the importance of legal processes in protecting investor rights.
- No-Risk Representation: Bronstein, Gewirtz & Grossman, LLC offers contingency fee representation, charging fees only upon successful recovery, which enhances investor confidence in participating in the class action lawsuit.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that the deadline to apply as lead plaintiff is May 26, allowing potential compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that executives made false statements regarding Anktiva's capabilities during the Class Period, resulting in investor losses when the truth emerged, highlighting significant governance and disclosure issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, as well as being ranked first for the number of settlements in 2017, indicating its expertise and success in this field.
- Investor Guidance: Investors are advised to select counsel with a proven track record rather than firms that merely act as intermediaries, ensuring they receive the best representation and support in litigation.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading statements made by its Chief Scientific Officer regarding Anktiva's efficacy during a podcast, involving investors from January 19 to March 24, 2026, highlighting significant risks in the company's information disclosure practices.
- FDA Warning Impact: The FDA issued a warning letter to ImmunityBio, indicating that its promotional materials misrepresented Anktiva's efficacy, resulting in a more than 21% drop in stock price on March 24, 2026, erasing nearly $2 billion in market capitalization, demonstrating the direct impact of regulatory risks on shareholder confidence.
- Investor Rights Protection: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to submit claims, reflecting the market's heightened concern over the company's transparency and compliance.
- Public Health Risks: The FDA emphasized that ImmunityBio's promotional materials could pose a public health threat due to misleading claims about Anktiva's efficacy, further underscoring the company's accountability issues in market promotion.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, or risk losing representation in the class action.
- Fee Arrangement: Investors participating in the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, allowing them to seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that executives at ImmunityBio made false or misleading statements during the class period, resulting in investor losses when the true information was revealed, indicating significant issues with the company's business and prospects.
- Law Firm's Strength: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling similar cases.
See More
